Literature DB >> 9373770

Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations.

R Banduwardene1, A B Mullen, K C Carter.   

Abstract

The anti-parasitic efficacy of free and a non-ionic surfactant vesicular (NIV) sodium stibogluconate (SSG) formulation of the drug, and their effect on the immune responses of Leishmania donovani infected BALB/c mice, was compared. The SSG NIV formulation maintained a significant suppression of splenic, hepatic and bone marrow parasite burdens (P < 0.005) compared to control values throughout the study. Infected controls and drug treated animals had high levels of L. donovani specific antibodies by day 14 of the study and the titre of these antibodies increased throughout the study for infected controls and free SSG treated animals. Initially SSG NIV treated animals had significantly higher specific IgG2a levels (P < 0.01, day 16) compared with infected controls and free SSG treated mice, but by day 31 the levels of this isotype and other antibodies (IgG1, IgG3 and IgM) were significantly lower (P < 0.05) than values for the other two groups. There was no difference in the proliferative responses of spleen cells taken from infected controls and drug treated animals to both specific and non-specific stimulation at day 16 of the study. On day 31, only spleen cells taken from infected mice given SSG NIV displayed a significant proliferative response to parasite antigen preparations and Concanavalin A stimulation (P < 0.01). No IL4 was detected in supernatants from in vitro spleen cells cultures. Significant levels of IFN-gamma was induced by stimulation of cells from vesicular drug treated animals with a frozen parasite preparation compared with medium controls (P < 0.05) on day 49 but not day 16. Similar stimulation did not induce IFN gamma production in spleen cells from infected controls or free drug treated animals. Only SSG NIV treated animals gave a significant positive DTH response to an L. donovani parasite preparation (P < 0.05) given on day 31. The results of this study indicate that there was a formulation dependent qualitative difference in the post-treatment immune responses of L. donovani infected animals, with SSG NIV animals displaying immune responses expected for a cured phenotype.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373770     DOI: 10.1016/s0192-0561(97)00009-x

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  7 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.

Authors:  Raul R Ribeiro; Eliane P Moura; Vitor M Pimentel; Weverton M Sampaio; Sydnei M Silva; Dante A Schettini; Cintia F Alves; Ferdinan A Melo; Wagner L Tafuri; Cynthia Demicheli; Maria N Melo; Frédéric Frézard; Marilene S M Michalick
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

3.  Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals.

Authors:  J Nieto; J Alvar; A B Mullen; K C Carter; C Rodríguez; M I San Andrés; M D San Andrés; A J Baillie; F González
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

4.  The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.

Authors:  K C Carter; A J Baillie; A B Mullen
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

5.  Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.

Authors:  A B Mullen; A J Baillie; K C Carter
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

6.  In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species.

Authors:  Louis Maes; Dirk Vanden Berghe; Nils Germonprez; Ludo Quirijnen; Paul Cos; Norbert De Kimpe; Luc Van Puyvelde
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

7.  Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis.

Authors:  Muzamil Y Want; Mohammad Islammudin; Garima Chouhan; Hani A Ozbak; Hassan A Hemeg; Asoke P Chattopadhyay; Farhat Afrin
Journal:  Int J Nanomedicine       Date:  2017-03-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.